Fortress Biotech, Inc.

FBIO

NASDAQ

Healthcare

Biotechnology

Bay Harbor Islands, FL, US101 employeesfortressbiotech.com

$2.56

+0.09(3.64%)

Mkt Cap $79M

$1.41

$4.38

52-Week Range

At a Glance

AI-generated

Fortress Biotech achieved net profitability in FY 2025 through strategic asset monetization, while its core operations continued to generate significant operating losses and cash burn, reflecting the ongoing challenge of converting R&D investments into sustainable commercial success.

Revenue breakdown: Qbrexza (42.5%), Accutane (27.4%), Emrosi (12.5%).

8-K

Fortress Biotech reported improved 2025 financial results with reduced net loss and announced significant corporate transactions, including the FDA approval of ZYCUBO® for Menkes disease and the $205 million sale of a Priority Review Voucher.

$79M

Market Cap

$71M

Revenue

$5M

Net Income

Employees101

Fundamentals

How The Business Makes Money

Revenue by Segment

Qbrexza42.5%($50M)

Accutane27.4%($32M)

Emrosi12.5%($15M)

Foam Franchise Products10.6%($13M)

Other Legacy Product Revenue5.7%($7M)

Collaborationrevenue1.3%($2M)

Activity

What Changed Recently

Financial Results

Mar 30, 2026

.** **Results of Operations and Financial Condition****.** On March 31, 2026, Fortress Biotech, Inc. issued a press release to provide a corporate update and

Material Agreement

Feb 22, 2026

. Entry into a Material Definitive Agreement . Priority Review Voucher Asset Purchase Agreement On February 22, 2026, Cyprium Therapeutics, Inc. (“Cyprium”)

Other Event

Mar 29, 2026

Other Events.** On March 30, 2026, Fortress Biotech, Inc. (the “ **Company** ”) issued a press release announcing the closing of the sale by Cyprium Therapeut

Other Event

Jan 12, 2026

. Other Events . On January 13, 2026, Fortress Biotech, Inc. (the “ Company ”) issued a press release announcing that the U.S. Food and Drug Administration (“

Peer Companies

Company	Price	Change	Market Cap	P/E
RLMDRelmada Therapeutics, Inc...	$7.00	-1.41%	$513M	-7.0
ADAGAdagene Inc.	$4.05	-12.15%	$153M	-3.8
VXRTVaxart, Inc.	$0.62	+1.61%	$150M	10.2
IMUXImmunic, Inc.	$1.15	-0.43%	$113M	-18.7
GANXGain Therapeutics, Inc.	$1.84	-4.90%	$78M	-3.4
XBITXBiotech Inc.	$2.35	+0.64%	$72M	-1.6
PMVPPMV Pharmaceuticals, Inc.	$1.33	+0.38%	$71M	-1.0
TCRXTScan Therapeutics, Inc.	$1.01	-1.46%	$58M	-1.0

Analyst View

Company Profile

CIK0001429260

ISINUS34960Q3074

CUSIP34960Q109

Phone781 652 4500

Address1111 Kane Concourse, Bay Harbor Islands, FL, 33154, US

SEC EDGAR